Disc Medicine, Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 67/100
What the filing says
Disc Medicine priced a public offering of 6,000,000 shares at $75.00 per share (gross proceeds ~$450M), with underwriters granted a 30-day option to purchase up to 900,000 additional shares at the same price. The offering closed October 22, 2026. Underwriters: Jefferies (1.62M shares), Leerink Partners (1.44M), Morgan Stanley (1.14M), Cantor Fitzgerald (0.93M), LifeSci Capital (0.33M), BMO Capital (0.36M), H.C. Wainwright (0.18M). Net proceeds will fund R&D, clinical development, commercialization of bitopertin for EPP/XLP, and general corporate purposes.
Why this rating
~$450M gross proceeds represents 32% of $1.4B market cap—material capital raise for clinical-stage biotech. Extends runway, funds pipeline advancement. Dilutive but strategically necessary.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.